Gene therapy for early amyotrophic lateral sclerosis
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests a new gene therapy called SNUG01 for people with ALS (a disease that weakens muscles). The goal is to see if it's safe and might slow down the disease, especially for those diagnosed within the last 2 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a definite or probable ALS diagnosis, and it's been 2 years or less since symptoms started.
- Your breathing is still fairly strong (based on breathing tests).
- Your ALS functional score (a measure of daily abilities) is at least 30, and your breathing-related scores are perfect.
- You have not had gene therapy, stem cell treatment, or an organ transplant in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
This study tests an experimental gene therapy called XT-150, which is given as an injection into the fluid around the spinal cord. The goal is to see if it is safe and to gather information that could help treat ALS muscle weakness.
This study tests a single injection given into the spinal fluid (intrathecal) to see if it is safe and might slow down ALS. It uses a specially engineered virus (AAV9) to deliver a treatment directly to the nervous system.
This trial tests a new type of cell therapy called regulatory T cells (Tregs) for people with neurodegenerative diseases like ALS. The goal is to see if these cells can slow down the disease.
This study tests an investigational drug called ALT001 in people with amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells controlling muscles. The goal is to see if ALT001 can help slow the progression of the disease. Participants will receive the drug and be monitored for safety and effects.
This trial tests a new treatment made from stem cells (called XS228CN) injected into the spine. It is primarily a safety study, but doctors will also watch for any signs the treatment may slow ALS progression.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.